Lymphosarcoma  >>  Xcytrin (motexafin gadolinum)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Xcytrin (motexafin gadolinum) / AbbVie
NCT00086034: Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma

Completed
2
35
US
Motexafin gadolinium
Pharmacyclics LLC.
Lymphoma, Non-Hodgkin's Lymphoma
 
 
NCT00100711: Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Terminated
2
27
US
Motexafin Gadolinium
Pharmacyclics LLC.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
02/10
 
NCT00290004: Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed
1/2
35
US
motexafin gadolinium
Pharmacyclics LLC.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Leukemia, Lymphoma
02/07
02/07

Download Options